Výsledky vyhledávání

Supplementary Data from Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

all supplementary files

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfb5414f1930e0247c2f633d7f46df3d
https://doi.org/10.1158/2159-8290.22531802.v1

Zobrazit plný text záznamu

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Publikováno v: Cancer Discovery. 8:1227-1236

The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA–C can result in significant clinical benefit in patients with diverse tumors harboring ALK, ROS1, or NTRK1–3 rearrangements; however, resistance invariably devel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13e2dbe9ec46916b6716b0f361624dfb
https://doi.org/10.1158/2159-8290.cd-18-0484

Zobrazit plný text záznamu

Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations

Autor: Wei Deng, Juliet Liu, Armin Graber, J. Jean Cui, Alexander Drilon, Robert C. Doebele, Alice T. Shaw, Shanna Stopatschinskaja, Xin Zhang, Evan Rogers, Sai-Hong Ignatius Ou, Jeeyun Lee, Byoung Chul Cho, Zhongdong Huang, Dong Lee, Dong Wan Kim, Jeffrey P. Whitten, Dayong Zhai

Publikováno v: Cancer Research. 79:442-442

Oncogenic TRKA/B/C fusions are identified in multiple cancer types in adults and children. TRK inhibitors (TRKis) have demonstrated marked efficacy in patients with these cancers, however, acquired on-target resistance mediated by kinase domain mutat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7d3264c7b7abe944e4ff268940942c10
https://doi.org/10.1158/1538-7445.am2019-442

Zobrazit plný text záznamu

Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study)

Autor: Byoung Chul Cho, Myung-Ju Ahn, Yuwei Juliet Liu, Viola W. Zhu, Alexander Drilon, Robert C. Doebele, Jingrong Jean Cui, Dong Wan Kim, Alice T. Shaw, D. Ross Camidge, David M. Hyman, Samuel Ejadi, Jessica J. Lin, Sai-Hong Ignatius Ou, Jeeyun Lee, Shanna Stopatschinskaja

Publikováno v: Journal of Clinical Oncology. 37:9011-9011

9011 Background: Repotrectinib is a next-generation ROS1/TRK/ALK TKI inhibiting ROS1 with > 90-fold greater potency than crizotinib. Preclinical studies showed robust kinase inhibitory activity of repotrectinib against all known ROS1 fusion positive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37e9c259616116abb3a629bd24b4d848
https://doi.org/10.1200/jco.2019.37.15_suppl.9011

Zobrazit plný text záznamu

OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer

Autor: Viola W. Zhu, A. Drilon, D. Kim, Juliet Liu, Alice T. Shaw, J. Jean Cui, David M. Hyman, Jessica Lin, J.W. Lee, D.R. Camidge, S-H.I. Ou, Robert C. Doebele, Byoung Chul Cho, M-J. Ahn, S. Shanna Stopatschinskaja

Publikováno v: Journal of Thoracic Oncology. 13:S1047

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af74a30ea11b413c2e8923e07c461d03
https://doi.org/10.1016/j.jtho.2018.10.019

Zobrazit plný text záznamu

Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells

Autor: Kevin J. Zwezdaryk, Donald G. Phinney, Aline B. Scandurro, Juliet Liu, Cindy Morris, Seth B. Coffelt, Gary W. Hoyle, Heather L. LaMarca, Yanira G. Figueroa, Luisa Florez

Publikováno v: Experimental hematology. 35(4)

Objective The ability of erythropoietin (EPO) to elicit a pro-angiogenic effect on human mesenchymal stem cells (hMSC) was tested. hMSC are currently under study as therapeutic delivery agents that target tumor vessels. Hypoxia favors the differentia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95275c1c8e9d24964b1bc18a2cb34053
https://pubmed.ncbi.nlm.nih.gov/17379074

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání